Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Traditional Chinese Medicine for Plasma Cell Mastitis
NCT05530226Phase 2Unknown
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- HMF (Herbal Medicine Formulation)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bazhengsan in Plasma cell mastitis (PCM), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Clinical cure rate and Clinical response rate. Status: unknown.
02
Drugs
bazhengsan
03
Conditions
Plasma cell mastitis (PCM)
Beyond the preview
Go deeper on NCT05530226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05530226.